Answer: adenylyl cyclase inositol triphosphate mainly known as IP3 causes the release of Calcium ions directly from the inracellular stores and causea contraction.
Explanation:
IP3, inositol phosphate is a second messenger a signaling molecule. It is made by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a phospholipid that is located in the plasma membrane, by an enzyme phospholipase C.
IP3 binds to the calcium channels and opens Ca2+ channels that are embedded in the ER membrane, releasing Ca2+ into the cytosol. Calcium ions released may cause contraction and regulate the Ca2+ channels in the membranes.
The time taken by light to reach pluto will be 5.6 hours.
<h3><u>Explanation</u>:</h3>
The light is a electromagnetic wave that has the highest velocity and same velocity as all other electromagnetic radiations existing in this universe. The light takes about 8.2 seconds to reach from sun to earth. So lets check howmuch time does light take to reach pluto from sun.
The speed of light was calculated to be 
m/s. This is the speed of each and every electromagnetic waves.
The distance of pluto from sun is huge. On an average it's 
km or 
m.
So time taken by light to reach from sun to pluto will be 
seconds. Or actually 5.6 hours.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
